Afatinib down-regulates MCL-1 expression through the PERK-eIF2a-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma

American Journal of Cancer Research

Volumn 6, Issue 8, 2016, Pages 1708-1719

  Liu, Xianfang ^a,b   Lv, Zhenghua ^a   Zou, Jidong ^a,b   Liu, Xiuxiu ^a   Ma, Juke ^a   Wang, Jinhua ^a   Sa, Na ^a   Jing, Peihang ^a   Xu, Wei ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Shandong Provincial Key Lab of Dermato venereology   (China)

Author keywords

Afatinib; Apoptosis; ATF4; eIF2 ; MCL 1; PERK

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; AFATINIB; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; PERK PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE SILENCING; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSLATION REGULATION;

EID: 85000399072     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Rothenberg SM and Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 2012; 122: 1951-1957.
2. Gold KA, Lee HY and Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922-935.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Yous-soufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
4. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D and Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
5. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS and Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
6. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A and Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-8424.
7. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E and Adolf GR. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342-350.
8. Wang XK, To KK, Huang LY, Xu JH, Yang K, Wang F, Huang ZC, Ye S and Fu LW. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget 2014; 5: 11971-11985.
9. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E and Cohen EE. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014; 25: 1813-1820.
10. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015; 16: 583-594.
11. Lee TG, Jeong EH, Kim SY, Kim HR and Kim CH. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int J Cancer 2015; 136: 2717-2729.
12. Chao TT, Wang CY, Chen YL, Lai CC, Chang FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ and Chen KF. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget 2015; 6: 2164-2179.
13. Zhan WJ, Zhu JF and Wang LM. Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment. Tumour Biol 2016; [Epub ahead of print].
14. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F and Cohen EE. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol 2015; 10: 501-508.
15. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
16. Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000; 2: 156-162.
17. Kang MH and Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
18. Youle RJ and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
19. Czabotar PE, Lessene G, Strasser A and Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
20. Mojsa B, Lassot I and Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 2014; 3: 418-437.
21. Caron A, Richard D and Laplante M. The Roles of mTOR Complexes in Lipid Metabolism. Annu Rev Nutr 2015; 35: 321-348.
22. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
23. Lauring J, Park BH and Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw 2013; 11: 670-678.
24. Szegezdi E, Logue SE, Gorman AM and Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006; 7: 880-885.
25. Bernales S, Soto MM and McCullagh E. Unfolded protein stress in the endoplasmic reticulum and mitochondria: a role in neurodegeneration. Front Aging Neurosci 2012; 4: 5.
26. Xu L, Su L and Liu X. PKCdelta regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells. Mol Cancer Ther 2012; 11: 2174-2182.
27. Li T, Su L, Zhong N, Hao X, Zhong D, Singhal S and Liu X. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy 2013; 9: 1057-1068.
28. Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X and Singhal S. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer 2011; 47: 2471-2478.
29. Liu X, Yue P, Zhou Z, Khuri FR and Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96: 1769-1780.
30. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW and Pelletier J. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 2008; 105: 10853-10858.
31. LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
32. Tasian SK, Teachey DT and Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front Oncol 2014; 4: 108.
33. Hiramatsu N, Chiang WC, Kurt TD, Sigurdson CJ and Lin JH. Multiple Mechanisms of Un-folded Protein Response-Induced Cell Death. Am J Pathol 2015; 185: 1800-1808.
34. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E and Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med 2013; 54: 936-943.
35. Wang SQ, Liu ST, Zhao BX, Yang FH, Wang YT, Liang QY, Sun YB, Liu Y, Song ZH, Cai Y and Li GF. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member. Oncotarget 2015; 6: 26142-26160.
36. Guan SS, Chang J, Cheng CC, Luo TY, Ho AS, Wang CC, Wu CT and Liu SH. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget 2014; 5: 4868-4880.
37. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev L, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M and Sarkar D. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20: 1397-1411.
38. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cellular and molecular life sciences: CMLS 2009; 66: 1326-1336.
39. Yoshida H. ER stress and diseases. FEBS J 2007; 274: 630-658.